Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Coronavirus Notebook: EMA Says ‘Wait And See’ On CureVac Data, EU Ministers Want Voluntary Approach To Sharing IP

Executive Summary

AstraZeneca and the European Commission have both claimed victory in the Vaxzevria supply case brought against the company by the commission. The Moderna coronavirus vaccine is now under review by the European Medicines Agency for use in younger people.

You may also be interested in...



Coronavirus Notebook: Australia ‘Recognizes’ Unapproved Vaccines, Russia Bigs Up Sputnik’s Chances At WHO

England’s NICE has given its backing to the use of Regeneron’s Ronapreve, and the UK’s new health security body is now fully up and running.

Pugatch: Pandemic Has Shown IPR-Based System Is Working

Pugatch Consilium managing director, Meir Perez Pugatch, says that IP has been the “bridge” in the various biopharma R&D collaborations that have helped deliver unprecedented results during the pandemic. He also weighs in on the divisive proposal of waiver of intellectual property rights for vaccines, treatments and diagnostics relating to COVID-19.

CureVac Still Hopes Variants Could Win Favor For COVID-19 Vaccine

Patients 18-60 had a protection rate of 53%, but there were too few cases among those older than 60 – a crucial subgroup – in HERALD to draw conclusions about the vaccine’s efficacy among older people.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS144504

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel